Moreau Michele, China Debarghya, Sy Gnagna, Ding Kai, Ngwa Wilfred
Department of Radiation Oncology and Molecular Radiation Sciences, Johns Hopkins University School of Medicine, Baltimore, MD 21287, USA.
Department of Biomedical Engineering, Johns Hopkins University School of Medicine, Baltimore, MD 21218, USA.
J Funct Biomater. 2024 Sep 27;15(10):285. doi: 10.3390/jfb15100285.
Smart radiotherapy biomaterials (SRBs) include seed and liquid biomaterials designed to be employed as fiducial markers during radiotherapy while also delivering therapeutic drug payloads to enhance treatment outcomes. In this study, we investigate a novel Customizable Lyophilized Agent for Radiotherapy Imaging and TherapY (CLARITY) biomaterial, which can be loaded with immunoadjuvants (anti-CD40 monoclonal antibody or Caflanone (FBL-03G)) at the point of care. The CLARITY biomaterial was investigated in an animal model of pancreatic cancer using C57BL6 mice. Mice were imaged before and at different points of time post-treatment to evaluate the potential of CLARITY biomaterial to provide imaging contrast similar to fiducials. This study also used cadavers to assess CLARITY's potential to provide imaging contrast in humans. Results showed imaging contrast from computed tomography (CT) and magnetic resonance imaging (MRI) modalities for up to 30 days post-treatment, demonstrating potential for use as fiducials. A significant increase in survival (, = 0.0006) was observed for mice treated with CLARITY biomaterial loaded with immunoadjuvant for up to 10 weeks post-treatment compared to those without treatment. These initial results demonstrate the potential of CLARITY biomaterial to serve as a smart multifunctional radiotherapy biomaterial and provide the impetus for further development and optimization as a point-of-care technology for combination radiotherapy and immunotherapy.
智能放射治疗生物材料（SRB）包括种子型和液体型生物材料，旨在在放射治疗期间用作基准标记物，同时还能递送治疗药物以提高治疗效果。在本研究中，我们研究了一种新型的用于放射治疗成像与治疗的定制冻干制剂（CLARITY）生物材料，其可在护理点加载免疫佐剂（抗CD40单克隆抗体或卡弗拉农（FBL - 03G））。使用C57BL6小鼠在胰腺癌动物模型中对CLARITY生物材料进行了研究。在治疗前及治疗后的不同时间点对小鼠进行成像，以评估CLARITY生物材料提供与基准标记物类似的成像对比度的潜力。本研究还使用尸体评估CLARITY在人体中提供成像对比度的潜力。结果显示，治疗后长达30天，计算机断层扫描（CT）和磁共振成像（MRI）模态均有成像对比度，表明其有作为基准标记物的潜力。与未治疗的小鼠相比，用加载免疫佐剂的CLARITY生物材料治疗的小鼠在治疗后长达10周的生存期有显著增加（， = 0.0006）。这些初步结果证明了CLARITY生物材料作为智能多功能放射治疗生物材料的潜力，并为其作为放射治疗与免疫治疗联合的护理点技术的进一步开发和优化提供了动力。
